(±)-BI-D

Cat. No.:	HY-18601
CAS No.:	1416258-16-6
Molecular Formula:	$C_{25}H_{27}NO_4$
Molecular Weight:	405.49
Target:	HIV; HIV Integrase
Pathway:	Anti-infection; Metabolic Enzyme/Protease
Storage:	Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year



SOLVENT & SOLUBILITY

In Vitro

DMSO : ≥ 100 mg/mL (246.62 mM)

* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Mass / Solvent / Concentration	1 mg	5 mg	10 mg
	1 mM	2.4662 mL	12.3308 mL	24.6615 mL
	5 mM	0.4932 mL	2.4662 mL	4.9323 mL
	10 mM	0.2466 mL	1.2331 mL	2.4662 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (6.17 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (6.17 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (6.17 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

(±)-BI-D is a potent ALLINI(An allosteric IN inhibitor) that binds integrase at the LEDGF/p75 binding site.IC50 value: 2.4–2.9 μM(HIV-Luc infection of WT and Hdgfrp2 KO cells) [1]Target: integrase inhibitorin vitro: Approximately 2.4–2.9 μM of BI-D was required to inhibit 50% of HIV-Luc infection of WT and Hdgfrp2 KO cells, while the IC50 decreased dramatically, to 160–200 nM, in Psip1 and double-KO cells [1].

CUSTOMER VALIDATION

- Cell Host Microbe. 2018 Sep 12;24(3):392-404.e8.
- Mbio. 2023 Feb 6;e0356022.
- J Virol. 2017 Apr 13;91(9). pii: e02155-16.
- Viruses. 2022, 14(9), 1883.
- Retrovirology. 2020 Aug 31;17(1):28.

See more customer validations on www.MedChemExpress.com

REFERENCES

[1]. Wang H, et al. HRP2 determines the efficiency and specificity of HIV-1 integration in LEDGF/p75 knockout cells but does not contribute to the antiviral activity of a potent LEDGF/p75-binding site integrase inhibitor. Nucleic Acids Res. 2012 Dec;40(22):11518-30.

[2]. Fader LD, et al. Minimizing the Contribution of Enterohepatic Recirculation to Clearance in Rat for the NCINI Class of Inhibitors of HIV. ACS Med Chem Lett. 2014 Apr 16;5(6):711-6.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA